No Data
shanghai titan scientific co.,ltd. (688133) Review of the third quarter report in 2024: Performance under pressure, waiting for a turnaround.
Item: In the first three quarters of 2024, the company achieved revenue of 2.126 billion yuan, a year-on-year increase of 3.49%; achieved net income attributable to the parent company of 0.01 billion yuan, a year-on-year decrease of 86.49%, with basic EPS of 0.06 yuan.
shanghai titan scientific co.,ltd. (688133): Entering a transformative period of improving profitability.
For companies in the scientific service sector, product capabilities, service capabilities, and production capabilities are all of great importance in development. shanghai titan scientific co.,ltd., as a rare full-process scientific service platform in the industry, has gradually passed the stage of strategic scale enhancement, and will further advance.
Zheshang: Innovative drugs, blood products and other fields may benefit from the slow recovery on the demand side.
Zheshang released research reports stating that the transition of pharmaceutical new and old kinetic energy will continue in the next stage, with innovative drugs, supply cleaning or better framework in areas such as innovative drug supporting industry chain, large infusion, anesthetic drugs, blood products, pharmaceutical circulation, traditional chinese medicine OTC, benefiting from the slow recovery on the demand side, potentially with better growth prospects.
shanghai titan scientific co.,ltd. (688133.SH): tianjin Chuangfeng and its concerted action persons hold a total shareholding of less than 5%.
shanghai titan scientific co.,ltd. (688133.SH) announced that the company recently received a notice from tianjin chuangfeng and its concerted action person: Ning...
Titan Technology: Titan Tech Third Quarter 2024 Report
Titan Technology 2024 Third Quarter Report
No Data
No Data